A Review; Prevalence, Causes and Treatment of Gout and Hyperuricemia


Mr. Sanket Pawar, Mr.Bhavesh Dandagvhal, Mr. Prasad Nikam, Miss. Mayuri Salave,
Miss. Vidya Ekhande, Miss. Pallavi Pagar, Miss. Sakshi Somani, Dr. Sanjay J. Kshirsagar, Dr. Eknath D. Ahire, Dr. Smita Kakad
Department of Pharmaceutics, METs institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Govardhan, Nashik, Maharashtra, India.


The purpose of this paper is to conduct a critical analysis of the data regarding the various therapeutic approaches for the management of hyperuricemia. In affluent nations, the burden of gout has increased due to an increase in the prevalence of both hyperuricemia and gout in recent decades. Imaging methods have shown to be helpful in identifying urate deposition even before the onset of clinical symptoms. This allows for the assessment of the degree of deposition and the monitoring of crystal depletion objectively during urate-lowering therapy. Treating to target is becoming a more popular method for treating a variety of illnesses. Consequently, distinct goals have been suggested for various phases of the disease burden and therapy phases. The ultimate strategic goal, towards which all efforts should be directed, is the total dissolution of urate crystals in tissues, thereby preventing additional symptoms and structural harm to the musculoskeletal structures involved. Keywords: Crystal deposition disease; Gout; Hyperuricemia; Uric acid